Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and jbt-3002

irinotecan has been researched along with jbt-3002 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fidler, IJ; Killion, JJ; Kumar, R; Kuniyasu, H; Shinohara, H1
Bucana, CD; Fidler, IJ; Killion, JJ; Shinohara, H; Yano, S1
Bruns, CJ; Davis, DW; Dong, Z; Fidler, IJ; Harbison, MT; Killion, JJ; McConkey, DJ; Nelkin, G; Shinohara, H1

Other Studies

3 other study(ies) available for irinotecan and jbt-3002

ArticleYear
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

    Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Intestinal Diseases; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms, Experimental; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C

1998
Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Survival; Cytoprotection; Ileum; Immunohistochemistry; Interleukin-15; Intestinal Mucosa; Irinotecan; Lipopeptides; Lipoproteins; Macrophages; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Transplantation; Rats; Specific Pathogen-Free Organisms

1999
Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
    Cancer research, 2000, Jan-01, Volume: 60, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Injections, Intralesional; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms; Lymph Nodes; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pancreatic Neoplasms; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured

2000